About Shionogi

  1. TOP > 
  2. About Shionogi > 
  3. 2019 Press Release

2019 Press Release

  • Jan
  • Feb
  • Mar
  • Apr
  • May
  • Jun
  • Jul
  • Aug
  • Sep
  • Oct
  • Nov
  • Dec

October

2019/10/30
Shionogi Announces Commencement of Tender Offer for Certificates of Shares, Etc. in UMN Pharma Inc. (Securities Code: 8840)
2019/10/28
Launch of “BNP Control Shionogi”, a Common Reference Standard Material for BNP Test
2019/10/28
Shionogi Provides Update on the Japanese Association for Infectious Diseases Statement and the Revised Guidelines of the Japanese Pediatric Society for the Treatment of Influenza
2019/10/18
FDA Approves XOFLUZA™ (Baloxavir Marboxil) for the Treatment of Acute Uncomplicated Influenza for People at High Risk of Developing Influenza-Related Complications
2019/10/18
Shionogi, Janssen, and Alzheimer’s Drug Discovery Foundation Announced a “Clinical Sample Access Agreement” at WDC 2019 Summit
2019/10/17
U.S. FDA Advisory Committee Recommends Approval of Cefiderocol for Treatment of Complicated Urinary Tract Infections
2019/10/16
Shionogi Filed for the Supplemental New Drug Application of XOFLUZA® in Japan for the Post-Exposure Prophylaxis of Influenza Virus Infection
2019/10/11
Shionogi Received “2019 Award for Excellence in Corporate Disclosure” for Three Consecutive Year from the Securities Analysts Association of Japan (SAAJ)
2019/10/11
Shionogi enters into a new license agreement and research collaboration for the treatment of mycobacterial diseases with Hsiri Therapeutics, Inc.
2019/10/04
M3 and Shionogi Joint Venture for Disease Solution - Establishment of Stream-I, Inc. -
2019/10/03
Shionogi Reports Positive Results from Cefiderocol Phase III Study in Adults with Pneumonia Caused by Gram-negative Pathogens APEKS-NP trial met primary endpoint of non-inferiority of cefiderocol compared to meropenem
2019/10/02
Congress Presentation on Clinical Study of S-600918, a Drug Candidate for the Treatment of Refractory/Unexplained Chronic Cough - Favorable Results of Phase II Study Presented at the European Respiratory Society International Congress (ERS 2019)

page top

page top